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Abstract
Background: Vitamin D is not only important for bone health but can also affect the development of several non-bone
diseases. The definition of vitamin D insufficiency by serum levels of 25-hydroxyvitamin D depends on the clinical outcome
but might also be a consequence of analytical methods used for the definition. Although numerous 25-hydroxyvitamin D
assays are available, their comparability is uncertain. We therefore aim to investigate the precision, accuracy and clinical
consequences of differences in performance between three common commercially available assays.
Methodology/Principal Findings: Serum 25-hydroxyvitamin D levels from 204 twins from the Swedish Twin Registry were
determined with high-pressure liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry (HPLC-
APCI-MS), a radioimmunoassay (RIA) and a chemiluminescent immunoassay (CLIA). High inter-assay disagreement was
found. Mean 25-hydroxyvitamin D levels were highest for the HPLC-APCI-MS technique (85 nmol/L, 95% CI 81–89),
intermediate for RIA (70 nmol/L, 95% CI 66–74) and lowest with CLIA (60 nmol/L, 95% CI 56–64). Using a 50-nmol/L cut-off,
8% of the subjects were insufficient using HPLC-APCI-MS, 22% with RIA and 43% by CLIA. Because of the heritable
component of 25-hydroxyvitamin D status, the accuracy of each method could indirectly be assessed by comparison of
within-twin pair correlations. The strongest correlation was found for HPLC-APCI-MS (r=0.7), intermediate for RIA (r=0.5)
and lowest for CLIA (r=0.4). Regression analyses between the methods revealed a non-uniform variance (p,0.0001)
depending on level of 25-hydroxyvitamin D.
Conclusions/Significance: There are substantial inter-assay differences in performance. The most valid method was HPLC-
APCI-MS. Calibration between 25-hydroxyvitamin D assays is intricate.
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Introduction
Vitamin D deficiency is not only associated with osteoporosis
and osteomalacia [1,2] but can also contribute to decreased
muscle strength [3], cancers [4], cardiovascular disease [5], type 1
diabetes mellitus [6] and overall mortality [7]. Defined risk groups
are elderly, dark-skinned and obese, as well as inhabitants in
northern latitudes where UV B radiation is undetectable during
winter [8,9,10,11]. These findings have increased the need for
determining vitamin D status in a reliable way.
Vitamin D exists in two forms, namely ergocalciferol (vitamin
D2), and cholecalciferol (vitamin D3). Vitamin D status is assessed
by measuring serum levels of 25-hydroxyvitamin D. Fatty fish and
dairy products are the main dietary sources of vitamin D3 [12,13].
The most important source of circulating 25-hydroxyvitamin D3
is, with sufficient solar exposure, the endogenous dermal
production of pre-vitamin D3 after exposure to UV B radiation
[8]. The less dominant serum 25-hydroxyvitamin D2 is mainly
derived from plant foods and in some countries from supplements.
There are many commercially available 25-hydroxyvitamin D
assays used for determination of vitamin D status. These include
high-pressure liquid chromatography (HPLC) and mass spec-
trometry (MS) [14], radioimmunoassays (RIA), enzyme immu-
noassays (EIA), competitive protein binding assays (CPBA),
automated chemiluminescence protein-binding assays (CLPBA)
and chemiluminescent immunoassays (CLIA). All these assays are
used in both clinical and research settings but it is not widely
appreciated that 25-hydroxyvitamin D assays may yield discrep-
ant results. Inter-assay and laboratory disagreement could
contribute to uncertainty when comparing results from studies
investigating the prevalence or clinical consequence of vitamin D
insufficiency. Indeed, several studies including reports from
DEQAS, an organization who aim to ensure the analytical
reliability of 25-hydroxyvitamin D assays [15], have indicated
high variability between different assays as well as inter-
laboratory disagreement, but these studies have been limited by
few participants, a non-population based setting, only partially
overlapping analyses of the samples included, and consensus
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11555opinion regarding accuracy rather than an unbiased comparator
[16,17,18,19,20,21,22].
25-hydroxyvitamin D levels are partially genetically determined
[23,24,25]. Higher twin resemblance in serum 25-hydroxyvitamin
D values indicates enhanced performance of the assay. This fact,
thus, enables that the within-pair correlation to be used as an
unbiased proxy measure of accuracy. Determination of accuracy
has not been possible in previous validation studies [16,17,
18,19,20,21]. In these studies, it has also not been evaluated if the
differences in assay results have been uniform or have been
dependent on serum 25-hydroxyvitamin D level. Cross-calibration
between assays is dependent on the pattern of assay differences.
We therefore aimed in a twin study to compare the differences in
performance between three common commercially available
methods for 25-hydroxyvitamin D analysis with different meth-
odological principles: a combined HPLC-MS method, a RIA and
a CLIA assay.
Materials and Methods
Ethics Statement
The study protocol was approved by the Ethics Committee of
Uppsala University and all participants gave written informed
consent to participate in the study and to donate blood samples.
Subjects
Subjects were recruited from The Swedish Twin Registry. All
intact like-sexed twin pairs, born 1965 or earlier and living in the
county of Uppsala were invited to participate. Uppsala County is
located in central Sweden at northern latitude 60u. Totally, 172
twin pairs were found eligible and invited to participate. Of these,
102 twin pairs, i.e. 204 subjects, accepted to participate in the
study. No subjects were excluded. Zygosity information in the
Swedish twin registry has a high validity [26]. The study included
59 female and 43 male Caucasian twin pairs with an age range
between 39 and 85 years. Because of low UV B radiation, vitamin
D cannot be synthesized in the skin between late autumn through
Table 1. Mean 25-hydroxyvitamin D (25(OH)D)) values and
characteristics of the twins as a function of season.
Total (n=204)
Mean (SD) Range
S-25(OH)D2+3 HPLC-APCI-MS (nmol/L) 85.0 (27.4) 21.42181.3
S-25(OH)D3 HPLC-APCI-MS (nmol/L) 83.3 (27.4) 21.42174.4
S-25(OH)D2 HPLC-APCI-MS (nmol/L)* 7.7 (2.8) 4.6213.9
S-25(OH)D RIA (nmol/L) 70 (24.0) 26.12156.5
S-25(OH)D CLIA (nmol/L) 59.9 (26.1) 10.02172.2
P-PTH (pmol/L) 1.9 (0.9) 0.425.3
Age (years) 57.5 (9.7) 37.8284.5
Weight (kg) 74 (12.2) 47.92122.6
Height (cm) 170.5 (9.7) 149.02194.5
Body mass index (kg/m
2) 25.4 (3.2) 18.9239.6
Mean 25-hydroxyvitamin D levels are adjusted for the twin-ship dependence.
*Results are based on the 40 (20%) participants who had measurable levels of
25-hydroxyvitamin D2.
doi:10.1371/journal.pone.0011555.t001
50
55
60
65
70
75
80
85
90
95
100
40
45
2
5
h
y
d
r
o
x
y
v
i
t
a
m
i
n
 
D
 
(
n
m
o
l
/
L
)
HPLC CLIA RIA
Figure 1. Mean serum 25-hydroxyvitamin D by assay. The error
bars indicate 95% confidence intervals.
doi:10.1371/journal.pone.0011555.g001
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Figure 2. Seasonal differences in 25-hydroxyvitamin D levels
for the HPLC-APCI-MS, RIA and CLIA assays. The error bars
indicate 95% confidence intervals.
doi:10.1371/journal.pone.0011555.g002
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November throughout April and summer as May throughout
October. The serum samples were collected during the winter
season for 28 twin pairs and during the summer season for 74
pairs. When possible, both members of each pair were examined
within the same week to take the individual seasonal variation in
vitamin D levels into account. Sixty-one pairs were examined the
same day. The median within pair difference in days between the
examinations among the remainder of the pairs was 6 days (inter
quartile range 2 to 9 days), with a maximum of 17 days. Seven
twins reported use of vitamin D supplements.
The study protocol was approved by the local ethical committee
of Uppsala and all participants gave written informed consent to
participate in the study and to donate blood samples.
Biochemical analyses
Venous blood samples were collected after a 12-h overnight
fasting, protected from light, centrifuged and stored at 280uC
until analysis. All samples were analyzed in three laboratories
using three techniques (described in detail below).
High-pressure liquid chromatography (HPLC) - atmo-
spheric pressure chemical ionisation (APCI) - mass
spectrometry (MS). Determination of 25-hydroxyvitamin D2
and D3 in plasma with HPLC-APCI-MS was done at Vitas, Oslo,
Norway. Deuterium labelled 25-hydroxyvitamin D2 and D3 were
used for internal standards. One hundred and fifty mL of human
plasma were diluted with 450 mL 2-propanol containing BHT
(butylhydroxytoluene) as an antioxidant. After thorough mixing
(15 min) and centrifugation (10 min, 4000 g at 10uC), an aliquot
of 35 mL was injected from the supernatant into the HPLC system.
HPLC was performed with a HP 1100 liquid chromatograph
(Agilent Technologies, Palo Alto CA, USA) interfaced by
atmospheric pressure chemical ionization (APCI) to a HP mass
spectrometric detector (MS) operated in single-ion monitoring
mode (SIM). 25-hydroxyvitamin D2 and D3 were separated on a
4.6 mm 650 mm reversed phase column with 1.8 mM particles.
The column temperature was 80uC. A two-point calibration curve
Table 2. Intraclass correlation coefficients (ICC) for serum 25-
hydroxyvitamin D levels between twins in a pair with 95%
confidence intervals.
Variable ICC (95% CI) P-value
HPLC-APCI-MS 0.66 (0.5420.76) ref NA
RIA 0.54 (0.3920.66) 0.004 ref
CLIA 0.40 (0.2220.55) ,0.001 ,0.001
The p-values correspond to a test of equality of the observed correlations.
doi:10.1371/journal.pone.0011555.t002
Table 3. Sample coefficient of variation (SCV) values with
95% confidence intervals.
Variable SCV% (95% CI)* P-value
HPLC-APCI-MS 32.3 (28.5236.0) ref NA
RIA 34.2 (29.8238.3) 0.243 ref
CLIA 43.5 (37.7248.9) ,0.001 0.001
*Adjusted for twin-ship dependence.
doi:10.1371/journal.pone.0011555.t003
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Figure 3. Cumulative proportion of the subjects who are classified as insufficient using a 50 nmol/L cut-off. HPLC-APCI-MS 8%, RIA
22%, CLIA 43%.
doi:10.1371/journal.pone.0011555.g003
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vitamin D concentration. Recovery is 95%; the method is linear
from 5–400 nmol/L and the limit of detection is 1–4 nmol/L.
The Coefficients of Variation (CV) for inter-assay analyses are
7.6% at 25-hydroxyvitamin D of 47.8 nmol/L and 6.9% at 25-
hydroxyvitamin D of 83.0 nM. The assay is accredited by the
Vitamin D External Quality Assessment Scheme (DEQAS) [15].
Radioimmunoassay (RIA). 25-hydroxyvitamin D2 and D3
in serum were measured at a research laboratory in Uppsala using
Gamma-B 25-hydroxyvitamin D RIA (IDS, Boldon, UK). The
CV for inter-assay analyses is 7.9%. Sensitivity, defined as the
concentration corresponding to the mean minus 2 standard
deviations of 10 replicates of the zero calibrator, is ,3 nmol/L.
To ascertain analytic quality all standards, controls and samples
were analyzed in duplicate and all duplicates with a coefficient of
variation .10% were reanalyzed. The control samples provided
by the manufacturer were within the recommended range.
Chemiluminescent immunoassay (CLIA). 25-hydroxy-
vitamin D2 and D3 in serum were measured as a standard
procedure at the department of Clinical Chemistry at Uppsala
University Hospital. The LIAISONH 25-hydroxyvitamin D Assay
(DiaSorin) uses chemiluminescent immunoassay technology.
Specific antibody to vitamin D is used for coating magnetic
particles (solid phase) and vitamin D is linked to an isoluminol
derivative. During the incubation, 25-hydroxyvitamin D is
dissociated from its binding protein and competes with labelled
vitamin D for binding sites on the antibody. After the incubation,
the unbound material is removed with a wash cycle. Subsequently,
the starter reagents are added and a flash chemiluminescent
reaction is initiated. The light signal is measured by a
photomultiplier as relative light units and is inversely
proportional to the concentration of 25-hydroxyvitamin D
present in samples. CV for inter-assay analyses is 18.4% at a 25-
hydroxyvitamin D level of 39.5 nmol/L and 11.7% at
121.25 nmol/L. The quality of the method is evaluated using
the Vitamin D External Quality Assessment Scheme (DEQAS)
[15] that is, based on blinded samples with varying concentrations
of 25(OH)D, sent out as a within- and between-method
comparison to over 500 participating laboratories, the assay
results agree within 630% of All Laboratory Trimmed Mean
(ALTM) [15].
Statistical analysis
The 25-hydroxyvitamin D values were normally distributed
with Shapiro-Wilk’s w value greater than 0.95. Mean serum 25-
hydroxyvitamin D values with 95% confidence intervals (CI) for
each assay results were calculated including stratification by
season. The cumulative proportion of twins at each serum level by
method was plotted in order to compare the proportion of twins
with values below each 25-hydroxyvitamin D level, specifically the
50 nmol/L insufficiency level proposed by expert opinion [28,29].
To estimate the accuracy of each method, resemblance in results
within twin pairs was calculated by intraclass correlation
coefficients (ICCs). The sample coefficient of variation (SCV)
was calculated by dividing the standard deviation for each method
by its mean value. Taking into account the twinship dependence,
bootstrap-estimated 95% confidence intervals of ICCs and SCVs,
and p values for assay differences, were obtained by re-sampling
the total sample size 10,000 times. Additionally, results of assays
were compared using Bland-Altman plots [30,31]. The difference
in performance by level of serum 25-hydroxyvitamin D was
formally tested by linear regression analysis of the difference in
absolute values between two methods regressed against the mean
of the method results of the two analyses, also taking into account
the twin-ship dependence and zygosity. A p-value ,0.05 was
considered significant.
Results
Our results reveal low inter-assay agreement. Mean 25-
hydroxyvitamin D values and basic characteristics of the twins
are presented in Table 1. HPLC-APCI-MS measured a mean 25-
hydroxyvitamin D level of 85 nmol/L, RIA 70 nmol/L and CLIA
60 nmol/L, p for difference between assays ,0.0001 (Figure 1).
25-hydroxyvitamin D2 was detectable in only 20% (n=40) of our
subjects using the HPLC-APCI-MS assay. The mean level among
these 40 twins was 8 nmol/L, and they contributed to only
1.5 nmol/L of the mean 25-hydroxyvitamin D level among all 204
twins. Demonstrated in Figure 2, the serum 25-hydroxyvitamin D
levels were significantly higher with all methods during the
summer compared to the winter season. The greatest inter-
seasonal difference, 23 nmol/L (95% CI 13–33), is presented by
the HPLC-APCI-MS assay.
There were considerable differences between the methods in
the proportion of participants classified as vitamin D insufficient.
Using a 50-nmol/L cut-off, only 8% of our subjects were
classified as vitamin D insufficient with the HPLC-APCI-MS
method, 22% using RIA and 43% with the CLIA method
(Figure 3).
As measures of assay accuracy, intraclass correlation coefficients
(ICC) for within twin pair similarity in 25-hydroxyvitamin D
levels, and 95% CI are presented in Table 2. HPLC-APCI-MS
had a significantly higher ICC relative to both RIA and CLIA,
and RIA had had a higher value than CLIA. The precision of the
assays was determined by sample coefficient of variation (SCV).
HPLC-APCI-MS had a SCV of 32%, RIA 34% and CLIA 44%
(Table 3).
According to the Bland-Altman plots, RIA and CLIA had a
non-proportional bias relative to HPLC-APCI-MS (Figure 4,
panel A–C). Both positive and negative bias became more
accentuated with increasing 25-hydroxyvitamin D value, i.e. the
inter-assay disagreement increases with an increasing serum level
of 25-hydroxyvitamin D. To formally test that there was a non-
uniform variability at different serum levels of 25-hydroxyvitamin
D between the methods we used linear regression to analyze the
relation between absolute differences in serum values between the
methods against the mean of the two values (Table 4). Both
parameter estimates were positive and highly statistically signifi-
cantly different from zero, and accordingly, the differences in
variation between the methods were higher at increasing levels of
serum 25-hydroxyvitamin D.
Discussion
We observed high variabilitybetweenthe HPLC-APCI-MS, RIA
andCLIA assayresults,emphasizingthata goldstandardforthe 25-
hydroxyvitamin D assay is needed to establish consensus on the
required level for sufficient vitamin D status. Highest accuracy was
found with the HPLC-APCI-MS and lowest with the CLIA
method.
Figure 4. Bland Altman plots for the difference in 25-hydroxyvitamin D level between the assays. HPLC-APCI-MS vs. RIA (panel A), HPLC-
APCI-MS vs. CLIA (panel B) and RIA vs. CLIA (panel C). Each circle represents one twin.
doi:10.1371/journal.pone.0011555.g004
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between different assays as well as inter-laboratory differences
using the same assay [16,17,18,19,21]. Lips et al [21] analyzed
samples from a selected population of vitamin D supplement users
(n=104) with three different methods. The mean 25-hydroxyvi-
tamin D level was 80% higher when using a competitive protein-
binding assay as compared with HPLC while intermediate values
were found with a RIA assay. The accuracy of the methods was
not possible to evaluate, however. Binkley et al reported 18% and
90% insufficiency proportions in two similar populations (n=20
and 42, respectively) using two RIA assays. IDS and DiaSorin-RIA
as well as a Nichols Advantage automated protein binding assay
detected less than 50% of the changes in 25-hydroxyvitamin D2
detected by HPLC according to Glendenning et al [19].
HPLC can discriminate 25-hydroxyvitamin D2 and D3
metabolites, whereas our RIA and CLIA method measure total
25-hydroxyvitamin D levels, i.e., the sum of 25-hydroxyvitamin D2
and D3 metabolites. In some countries, including the USA,
vitamin D2 has been the only form of vitamin D available for
prescription, even though both vitamin D2 and vitamin D3 are
used as non-prescribed supplements, while in Europe vitamin D3 is
dominating [32]. HPLC could therefore have an advantage when
evaluating the effect of supplementation with D2. Nevertheless,
this is of minor importance in our setting since only 20% of our
participants have measurable 25-hydroxyvitamin D2 values,
contributing on average to only 2% higher total 25-hydroxyvita-
min D levels in the cohort. Similar low values were found by
Ho ¨gstro ¨m et al [33] in young, healthy Swedish men. Thus, in
European countries it may not be of major clinical importance
that some assays underestimate D2 (although not relevant to our
study) or cannot separate between D2 and D3.
There is no well defined and international accepted definition of
optimal serum 25-hydroxyvitamin D value for bone and
nutritional health [28,29], but low plasma 25-hydroxyvitamin D
and secondary hyperparathyroidism are the biochemical hall-
marks for insufficient vitamin D status [2]. A common definition of
vitamin D insufficiency is 25-hydroxyvitamin D ,50 nmol/L
although many authors suggest that clinicians should aim at higher
levels [28,29,34]. Our great inter-assay differences in insufficiency
proportion, as well as in accuracy and in precision indicate that it
is questionable to rely on immunoassays when determining
whether a patient is insufficient. Some assays may be too imprecise
for both clinical and research use. Assay-specific decision limits to
define appropriate thresholds for insufficiency have been suggested
as a solution [19] but that will be cumbersome for the clinician.
Furthermore, our results suggest that a simple reliable calibration
between assays cannot be accomplished.
Assay disagreement and inter-laboratory variation naturally
have important clinical implications. It may hamper comparison
of studies from diverse populations and countries, exemplified by
Lips [21]. This may be the reason why there is inconsistent
evidence regarding the degree of association between vitamin D
status, bone mineral density and the risk of low energy fractures
[35].
Because the HPLC-APCI-MS method provides the most
prominent difference between summer and winter levels of 25-
hydroxyvitamin D, the lowest SCV value and the best twin
resemblance in serum levels, our conclusion is that HPLC-APCI-
MS is a more accurate and reliable method than both RIA and
CLIA.
The advantages of our study are the comparable large sample
size, the population-based design, that our participants comprised
of twins and that all the samples are analyzed with all three assays.
One limitation is that other available methods for 25-hydro-
xyvitamin D measurement were not evaluated. Moreover, with
analyses performed at three laboratories, such a design could limit
the ability to separate assay-specific from laboratory-specific bias.
Differences between laboratories may be caused by unfamiliarity
with the analytical method, but all laboratories in our study were
experienced with the method used at that site and all methods are
used for clinical decision making. Moreover, Vitas is an approved
R&D institution in the SkatteFUNN scheme held by the
Norwegian Research Council and is the national reference
laboratory for vitamin D analysis. The department of Clinical
Chemistry at the Uppsala University Hospital is accredited by the
Swedish Board for Accreditation and Conformity Assessment
(SWEDAC). SWEDAC must in its turn fulfil certain requirements
that are set out in ISO/IEC 17011. Compliance is confirmed by
the international assessments that are performed within the
framework of the European Accreditation cooperation (EA).
We conclude that a single threshold value to define an optimal
25-hydroxyvitamin D level is presently impossible to determine
because of differences in assay results.
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